ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
MICA gene modulates immune microenvironment and comorbid mechanisms in diffuse large B-cell lymphoma and primary Sjögren's syndrome.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo identify shared molecular mechanisms and crosstalk genes (CGs) between diffuse large B-cell lymphoma (DLBCL) and primary Sjögren's syndrome (PSS), and to explore the role of MICA in the immune microenvironment (IME).
methodsBioinformatics analysis of GEO datasets identified differentially expressed genes (DEGs). Enrichment, immune infiltration, and Mendelian randomization analyses were performed. Diagnostic biomarkers were screened using Lasso regression. Functional roles of MICA were validated in SUDHL-6 cells via overexpression/knockdown, assessing immune cell infiltration, cytokine secretion, proliferation, and apoptosis.
resultsWe identified 50 shared DEGs. RPL31, HNMT, and IFI27 were defined as diagnostic biomarkers. MR analysis confirmed a causal effect of PSS on DLBCL risk. MICA interacted with RPL31 and HNMT. MICA overexpression enhanced CD8
conclusionMICA plays a key role in shaping the immune microenvironment of DLBCL and PSS. By reinforcing anti-tumor immune responses and limiting tumor growth, it emerges as a promising biomarker and therapeutic target in both diseases.
Indexed as
Identifiers
42536179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.